NHL

Minnesota Wild Announce TicketManager as Official Ticket Management and Corporate Re-Sale Partner

Retrieved on: 
Tuesday, February 7, 2023
Retail, Specialty, Sports, Hockey, NHL, ROI, Minneapolis–Saint Paul, Basketball, MLS, Mastercard, Anheuser-Busch, FedEx, Football, Sale, Senior, NBA, Minnesota Wild, MLB, Sport, NFL, Movement, Verizon Communications, Baseball, Partnership, NCAA, Xcel Energy Center, Wild, Ticketmaster, Multimedia, CO, Airline, Online shopping, Adidas, Nissan

View the full release here: https://www.businesswire.com/news/home/20230207005500/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230207005500/en/
    Minnesota Wild and TicketManager partner to help companies get the most use and best ROI from corporate tickets including re-sale powered by Ticketmaster (Graphic: Business Wire)
    The Wild’s business customers can use TicketManager at no charge to centralize ticket distribution, approval and delivery, as well as access reports on ticket usage, including who scanned tickets at the gate.
  • Those businesses can use TicketManager for all live events in the Twin Cities area, including baseball, football, basketball, hockey and college sports at no cost.
  • In addition, team partners will be able to responsibly recapture the value of any unused tickets by using TicketManager to sell unused tickets through the teams ticketing partner, Ticketmaster.
  • “We’re very excited to welcome TicketManager as a new partner,” said Carin Anderson, Senior Vice President of Corporate Partnerships and Retail Management for the Wild.

The EV Market Moves Beyond AM & FM; TuneIn and XPENG Join Forces to Reimagine In-Car Streaming Audio

Retrieved on: 
Tuesday, February 7, 2023
Software, EV, Electric Vehicles, Entertainment, Internet, Mobile Entertainment, Podcast, Apps, Applications, Technology, Automotive, TV and Radio, Music, Audio, Video, NHL, Fox News Radio, System, NYSE, RTL, NRJ, OEM, News, XPEV, NBA, EVS, Partnership, MSNBC, CNN, SUV, Bloomberg, Mobile phone, XPENG, TuneIn, EU

TuneIn, the world’s leading live-streaming audio service, announced today a new partnership deal with XPENG (NYSE: XPEV), a leading Chinese smart electric vehicle company.

Key Points: 
  • TuneIn, the world’s leading live-streaming audio service, announced today a new partnership deal with XPENG (NYSE: XPEV), a leading Chinese smart electric vehicle company.
  • Through this partnership, the TuneIn app will be integrated into XPENG’s lineup of vehicles including the flagship sedan and SUV models.
  • TuneIn is modernizing the car audio experience by integrating digital radio and podcasts in new EVs released into the global market.
  • The TuneIn service in XPENG vehicles provides access to live sports, 24-hour newscasts, continuous music, and podcasts from around the world through a seamless infotainment system integration in XPENG vehicles.

SeatGeek Partners with Paciolan, the Largest Ticketing Company in College Athletics

Retrieved on: 
Monday, February 6, 2023
General Sports, Sports, University, Events, Concerts, Online Retail, Education, Retail, Entertainment, NHL, Devon Walker, Watford F.C., API, Deal, Utah Jazz, NBA, Sport, NFL, Student, Premier League, Partnership, 1984–85 Wolverhampton Wanderers F.C. season, Power Five conferences, Soundscape Digital Technology, New Orleans Saints, Official, Name, Music, Online shopping, SeatGeek, Comcast Spectacor

SeatGeek’s secondary ticketing services will be directly integrated with Paciolan’s primary ticketing system with an expected start date in July 2023.

Key Points: 
  • SeatGeek’s secondary ticketing services will be directly integrated with Paciolan’s primary ticketing system with an expected start date in July 2023.
  • College sports have quickly become the fastest growing and most dynamic sector in live entertainment, ready for innovation,” said Russ D’Souza, co-founder of SeatGeek.
  • Paciolan renewed over 30 partners and grew its roster with 12 new clients in 2022, adding to its impressive community of 160 college athletics clients and hundreds of live entertainment venues.
  • Paciolan has the largest presence in college athletics ticketing, working with 80 percent of the Power Five conference schools.

Bayer® Aspirin Continues Long-standing Commitment to Heart Health Education, Encouraging Sports Fans to Keep Their Heart in the Game as the Official Sponsor of Fans’ Hearts

Retrieved on: 
Monday, February 6, 2023
General Sports, Health, Media, Pharmaceutical, Other Education, Sports, Public Relations, Investor Relations, Marketing, Influencer, Education, General Health, Communications, Fitness & Nutrition, Cardiology, NA, NHL, Woman, Keep Your Heart Right, Los Angeles Dodgers, LA, Bayer, American Heart Month, Aspirin, NBA, Risk, Bally Sports, NFL, Cardiovascular disease, Death, Heart, Multimedia, Sport, ESPN, NBC Sports, Pharmaceutical industry, Dietary supplement, Entertainment, Pain

In recognition of American Heart Month, Bayer is continuing its ongoing commitment to elevating awareness and education about heart health and risk factors for cardiovascular disease.

Key Points: 
  • In recognition of American Heart Month, Bayer is continuing its ongoing commitment to elevating awareness and education about heart health and risk factors for cardiovascular disease.
  • In fact, heart attack risk can more than double when your home team plays.
  • View the full release here: https://www.businesswire.com/news/home/20230206005102/en/
    To reach people where they are, Bayer® Aspirin is showing up for fans who put their whole hearts into their fandom as the Official Sponsor of Fans’ Hearts, encouraging fans, and non-fans alike, to prioritize their heart health by assessing their risk factors for cardiovascular disease at CheckYourHeartRisks.com.
  • And follow along on Bayer® Aspirin social channels (Instagram: @BayerAspirin_US ; Facebook: @BayerAspirin ).

JAYPIRCA™ (pirtobrutinib) Now Available from Onco360 for the Treatment of Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma (MCL) after at least Two Lines of Systemic Therapy, Including a BTK Inhibitor

Retrieved on: 
Wednesday, February 1, 2023
Pharmaceutical, Health, Oncology, MCL, NHL, Fatigue, Lymphoma, Edema, Diarrhea, Treatment, National Cancer Institute, Non-Hodgkin lymphoma, Pneumonia, Specialty pharmacy, Mantle cell lymphoma, Patient, SEER, United, Eli Lilly, ORR, NCCN, Disease, Partnership, FDA, National Comprehensive Cancer Network, DSM-IV codes, Death, Periodic breathing, Pharmaceutical industry, Epidemiology

Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

Key Points: 
  • Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
  • “Onco360 is excited to announce our partnership with Eli Lilly and become a specialty pharmacy provider for JAYPIRCA patients,” said Benito Fernandez, Chief Commercial Officer, Onco360.
  • The five-year overall survival (OS) for MCL ranges from 50-70% dependent upon stage of disease.2
    JAYPIRCA, a non-covalent BTKi, is commercialized by Eli Lilly.
  • The most common adverse reactions (> 15%) in patients with MCL are fatigue, musculoskeletal pain, diarrhea, edema, dyspnea, pneumonia, and bruising.3

Let's Run it Back: SeatGeek Extends its Partnership with the New Orleans Pelicans

Retrieved on: 
Tuesday, January 31, 2023
Sports, General Entertainment, Technology, Apps, Applications, Events, Concerts, Electronic Commerce, Basketball, Entertainment, Football, NHL, Pels, USL, United Soccer League, NASCAR, Watford F.C., Senior, NBA, Florida Panthers, NFL, Utah Jazz, Marketing, Partnership, Growth, Baltimore Ravens, Fiesta Bowl, Washington Commanders, Sport, SeatGeek, Saint

SeatGeek , the high-growth technology platform transforming the live event experience for fans, teams and venues, today announced a renewal of its partnership with the NBA’s New Orleans Pelicans.

Key Points: 
  • SeatGeek , the high-growth technology platform transforming the live event experience for fans, teams and venues, today announced a renewal of its partnership with the NBA’s New Orleans Pelicans.
  • The organization joins a deep bench of clients who have extended their partnership with SeatGeek.
  • In the last 18 months, SeatGeek has seen a 96% partnership renewal rate of its global client base.
  • The Pelicans, like the Saints, use centralized, comprehensive data reports from all open-distribution sales channels and query builders to optimize marketing and revenue.

Artiva Biotherapeutics Receives FDA Fast Track Designation for AB-101

Retrieved on: 
Tuesday, January 31, 2023
Science, Other Science, Research, General Health, Health, FDA, Genetics, Clinical Trials, NHL, Food, Rituximab, Protalix BioTherapeutics, Lymphoma, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Hodgkin lymphoma, NK, Fast Track, Patient, Pharmaceutical industry

Artiva Biotherapeutics, Inc. , a clinical stage company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer (NK) cell-based therapies, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Artiva’s lead program AB-101.

Key Points: 
  • Artiva Biotherapeutics, Inc. , a clinical stage company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer (NK) cell-based therapies, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Artiva’s lead program AB-101.
  • “We are excited to announce this advantageous regulatory designation as we continue our clinical evaluation of the AB-101/rituximab combination in the treatment of relapsed/refractory B-cell NHL, including in patients who have failed prior CAR-T treatment,” said Thorsten Graef, M.D., Chief Medical Officer of Artiva.
  • “We are encouraged by the early clinical data we are seeing with AB-101 and look forward to expanding its evaluation in this indication as well as with additional biologic therapy combinations through internal and partnered clinical programs.”
    “We are committed to our mission of delivering AB-101 as an off-the-shelf cell therapy with an efficacy and tolerability profile suitable for administration and management in the community setting,” stated Fred Aslan, M.D., Chief Executive Officer of Artiva.
  • “Given the maturity of our highly scalable manufacturing process, we believe we are well positioned to pursue a first-in-class allogeneic NK cell therapy registration in either non-Hodgkin lymphoma in combination with rituximab, or in Hodgkin lymphoma in combination with Affimed’s AFM13.”

Electronic Arts Reports Q3 FY23 Financial Results

Retrieved on: 
Tuesday, January 31, 2023
Sports, eSports, General Sports, Consumer Electronics, Technology, Electronic Games, Online, Mobile Entertainment, General Entertainment, Entertainment, Other Technology, EA, CFO, NHL, Electronic Arts, Sims, NHL 23, Pop Art, Inc., IP, AAA, History, Video game, Holding company

Electronic Arts Inc. (NASDAQ:EA) today announced preliminary financial results for its third fiscal quarter ended December 31, 2022.

Key Points: 
  • Electronic Arts Inc. (NASDAQ:EA) today announced preliminary financial results for its third fiscal quarter ended December 31, 2022.
  • “In Q3, EA delivered high-quality experiences, driving record engagement across some of our biggest franchises and growing our player network.
  • While our teams delivered for our players, the current macro environment impacted Q3 results,” said Andrew Wilson, CEO of Electronic Arts.
  • EA SPORTS FIFA 23 is pacing to be the biggest title in franchise history and delivered record engagement in Q3.

The Northwest Event Show Announces Tracks and Session Lineup for 2023: Summit at the Summit in Seattle

Retrieved on: 
Wednesday, February 15, 2023
Kraken, NHL, Drama, Student, Time to Change (mental health campaign), New York State School of Industrial and Labor Relations at Cornell University, MPI, Seattle Kraken, PCMA, Microsoft, Business, Pacific Northwest, Artificial intelligence, NWES, BDA, PAS, Summit, Seattle Convention Center, Summit Building (Midland), ILEA, Education, Innovation, NACE, All Access, Video game, Online shopping

SEATTLE, Feb. 15, 2023 /PRNewswire/ -- The Northwest Event Show (NWES), the premier events industry show for the west coast, is pleased to unveil the tracks and sessions for the upcoming education series at the event – Summit at the Summit. The west coast gathering will be held in the Pacific Northwest March 15-16 at the brand new, award-winning Summit Building at the Seattle Convention Center, with virtual access also available.

Key Points: 
  • SEATTLE, Feb. 15, 2023 /PRNewswire/ -- The Northwest Event Show (NWES), the premier events industry show for the west coast, is pleased to unveil the tracks and sessions for the upcoming education series at the event – Summit at the Summit .
  • The west coast gathering will be held in the Pacific Northwest March 15-16 at the brand new, award-winning Summit Building at the Seattle Convention Center, with virtual access also available.
  • For the latest updates and speaker announcements, follow the Northwest Event Show on LinkedIn at https://www.linkedin.com/company/nweventshow/ or on Instagram at https://www.instagram.com/nweventshow/ , or opt-in to receive the Northwest Event Show Newsletter at https://nweventshow.com/#newsletter .
  • To register and purchase tickets for the Assistant Masterclass and The Northwest Event Show, visit https://nweventshow.com/2023-tickets/ .

FCS Clinical Trials Lead to FDA Approval of New Targeted Drug for Patients with Mantle Cell Lymphoma

Retrieved on: 
Tuesday, February 14, 2023
AOCNP, MCL, NHL, Estate (law), Spleen, Drug development, National Institute of Nursing Research, FCS, Abstract, B-cell lymphoma, Reversibility, Diagnosis, Safety, Bone marrow, Hematology, Patient, Clinician Administered PTSD Scale, Liver, Lymph, Mantle cell lymphoma, Relapse, FACP, Clinical research, FDA, Growth, Prognosis, MSN, Progression-free survival, Society, BTK, Cancer, MD, Pharmaceutical industry, Vaccine

"It is rewarding to see the impact of our work in developing this drug from the initial trial."

Key Points: 
  • "It is rewarding to see the impact of our work in developing this drug from the initial trial."
  • - Manish Patel, MD
    Pirtobrutinib (Jaypirca™) is the first next-generation BTK inhibitor specifically approved by the FDA for adult patients with mantle cell lymphoma (MCL), a rare type of non-Hodgkin's lymphoma (NHL), which affects about one in 200,000 people worldwide each year.
  • Following an expedited review of the outcomes observed in the BRUIN 18001 study, the FDA granted Pirtobrutinib an accelerated approval.
  • To read the full study abstract: https://ash.confex.com/ash/2022/webprogram/Paper157058.html
    Access the current list of FCS clinical trials: https://flcancer.com/clinical-trials/